These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7199979)

  • 1. Fibrinogen degradation products (F.D.P.) in ascitic fluid of patients affected by ovarian cancer.
    Paternoster D; Maggino T; Valente S; Paternoster A; Pengo V; Marchesoni D
    Clin Exp Obstet Gynecol; 1981; 8(2):64-5. PubMed ID: 7199979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrinogen degradation products (F.D.P.) in ascitic fluid of patients affected by ovarian cancer.
    Paternoster D; Maggino T; Valente S; Pengo V; Marchesoni D
    Eur J Gynaecol Oncol; 1981; 2(3):127-8. PubMed ID: 7347682
    [No Abstract]   [Full Text] [Related]  

  • 3. [Markerfunction of crosslinked fibrin derivatives in ascitic fluid from patients with ovarian cancer: a comparison with ascitic fluid in liver cirrhosis].
    Graeff H; Klaubert W; Klaubert E; Gollwitzer R; von Hugo R; Hafter R
    Geburtshilfe Frauenheilkd; 1983 Jun; 43 Suppl 1():42-6. PubMed ID: 6555132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coagulative and fibrinolytic properties of ascitic fluid associated with ovarian tumors.
    Svanberg L; Astedt B
    Cancer; 1975 May; 35(5):1382-7. PubMed ID: 47263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crosslinked fibrin derivatives and fibronectin in ascitic fluid from patients with ovarian cancer compared to ascitic fluid in liver cirrhosis.
    Hafter R; Klaubert W; Gollwitzer R; von Hugo R; Graeff H
    Thromb Res; 1984 Jul; 35(1):53-64. PubMed ID: 6474409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical significance of ascitic fluid FDP and fibrinolytic activity assay].
    Lu XG; Chen CS; Ye ZY
    Zhonghua Nei Ke Za Zhi; 1987 Sep; 26(9):530-2, 565. PubMed ID: 3450474
    [No Abstract]   [Full Text] [Related]  

  • 7. Fibrin degradation products and ovarian tumours.
    Astedt B; Svanberg L; Nilsson IM
    Br Med J; 1971 Nov; 4(5785):458-9. PubMed ID: 4256596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrinolysis in ascitic fluid: isolation and characterization of fibrin derivatives, their interaction with albumin.
    Wilhelm O; Hafter R; Graeff H
    Thromb Res; 1987 Sep; 47(6):673-81. PubMed ID: 3686482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Identification of fibrinogen or fibrin degradation products in the ascitic fluid].
    Kolodie L; Detante J; Rachail M
    Nouv Presse Med; 1978 Feb; 7(8):665. PubMed ID: 417295
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation and comparison of hemocoagulation parameters both in serum and in ascites from patients with gynecologic malignancies.
    Varcaccio-Garofalo G; Selvaggi L; Capozza G; Orlando E; Ferreri R; Restaino A
    Eur J Gynaecol Oncol; 1982; 3(2):113-4. PubMed ID: 7166171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Relation between fibrin/fibrinogen degradation products in malignant fluids and the fibrinolytic activity of the peritoneum].
    Takahashi M; Yoshida K; Kano K; Machida T; Nakamura Y; Miura Y; Miura N; Kanno S
    Gan No Rinsho; 1986 Dec; 32(15):1945-9. PubMed ID: 3806965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites.
    Thaler J; Lisman T; Quehenberger P; Hell L; Schwabl P; Scheiner B; Bucsics T; Nieuwland R; Ay C; Trauner M; Pabinger I; Reiberger T; Mandorfer M
    Thromb Haemost; 2022 Mar; 122(3):353-362. PubMed ID: 34020489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comments on the paper by Schröck et al., The simultaneous determination of Ca 125 and D-dimer in plasma and ascitic fluid in ovarian cancer].
    Mezger J
    Onkologie; 1986 Feb; 9(1):10. PubMed ID: 3523340
    [No Abstract]   [Full Text] [Related]  

  • 14. Early diagnosis of ovarian cancer.
    Popkin DR
    Can Med Assoc J; 1979 May; 120(9):1106-8. PubMed ID: 445304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Release of fibrinolytic activators from human ovarian tumours in organ culture.
    Svanberg L; Astedt B
    Ann Chir Gynaecol; 1976; 65(6):405-7. PubMed ID: 1020906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human ovarian cancer ascites fluid contains a mixture of incompletely degraded soluble products of fibrin that collectively possess an antiangiogenic property.
    Jandu N; Richardson M; Singh G; Hirte H; Hatton MW
    Int J Gynecol Cancer; 2006; 16(4):1536-44. PubMed ID: 16884362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ascites fluid as a possible origin for hyperfibrinolysis in advanced liver disease.
    Agarwal S; Joyner KA; Swaim MW
    Am J Gastroenterol; 2000 Nov; 95(11):3218-24. PubMed ID: 11095345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of plasmin in the degradation of the stroma-derived fibrin in human ovarian carcinoma.
    Wilhelm O; Hafter R; Henschen A; Schmitt M; Graeff H
    Blood; 1990 Apr; 75(8):1673-8. PubMed ID: 2139349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemostatic Findings in Ascitic Fluid: A Cross-Sectional Study in 70 Dogs.
    Zoia A; Drigo M; Piek CJ; Simioni P; Caldin M
    J Vet Intern Med; 2017 Jan; 31(1):43-50. PubMed ID: 27862300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Coagulant and procoagulant factors in ascitic fluid--about etiology DIC induced by ascitic fluid infusion (author's transl)].
    Ojiro M
    Igaku Kenkyu; 1981 Oct; 51(4):177-85. PubMed ID: 7331734
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.